Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression
NCT ID: NCT07226232
Last Updated: 2025-11-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE3
240 participants
INTERVENTIONAL
2026-06-01
2031-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The purpose of this multi-site, double-blind, randomized controlled trial is to evaluate the efficacy and risks of psilocybin for the treatment of TRD in U.S. military Veterans with and without (±) concurrent PTSD. Eligible and consenting Veterans will two psilocybin dosing sessions along with preparation, administration, and integration psychological support provided by a facilitator. For the 1st psilocybin administration, participants will be randomized to one of two doses under blinded conditions. One month later, all participants will receive a 25mg dose at their 2nd psilocybin visit. Outcomes will be measured by an independent evaluator masked from all treatments at 2 and 4 weeks after each dosing session. Longer-term follow-up will be conducted over 6 months. Both expected and unanticipated adverse events will be collected by type, severity and relatedness to the study drug.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
For the 1st of 2 dosing sessions, Veterans are randomized to receive one of two doses of psilocybin. One month later, participants return for a 2nd psilocybin dosing session in which all participants get the same dose of psilocybin.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control
Psilocybin comparator dose
Psilocybin
Psilocybin comparator dose
Intervention
Psilocybin intervention dose
Psilocybin
Psilocybin Intervention Dose
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Psilocybin
Psilocybin comparator dose
Psilocybin
Psilocybin Intervention Dose
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Signed informed consent and HIPAA
* Adults \</= 75 years of age
* Meets DSM-5 criteria for current major depressive episode (MDE)
* MADRS \>/= 20 at baseline
* Failure to respond satisfactorily to \>/= 2 antidepressant treatments for \>/= 8 weeks, including \>/= 2 weeks at an adequate dose (\>/= 50% of the FDA-approved uppermost dose) for major depression. Augmentation with a medication for depression (e.g., neuroleptics, lithium, levothyroxine) is considered a separate course of treatment.
* If applicable, concurrent \& permitted antidepressants must be at stable doses for \>/= 4 weeks prior to baseline (see allowed \& prohibited medication list)
* Participants of child-bearing potential must have negative pregnancy test \& agree to adhere to a medically acceptable method of birth control during the study
* Has a responsible adult who will provide transportation to the participant's home or place of lodging on the days of psilocybin administration
Exclusion Criteria
* First-degree relative with history of bipolar I, schizophrenia spectrum or other psychotic disorder
* Presence of psychotic symptoms (e.g., MDE with psychotic symptoms)
* Sedative-hypnotic, stimulant, inhalant and/or opioid use disorder within past 6 months (lifetime substance use disorder is allowed at the discretion of the LSI)
* Severe alcohol and/or cannabis use disorder within the past 6 months (mild or moderate alcohol and/or cannabis use is allowed at the discretion of the LSI)
* Lifetime hallucinogen persisting perception or hallucinogen use disorders
* Use of psilocybin, ayahuasca, mescaline, lysergic acid diethylamide (LSD), dimethyltryptamine (DMT), 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT), peyote, or 3,4-methylenedioxymethamphetamine (MDMA) within past 6 months
* Participant agrees to not use psychedelics (listed above) during the study, except as prescribed by the study protocol
* Taking prohibited medication within 2 weeks of baseline (see allowed and prohibited concomitant medication list)
* History of severe traumatic brain injury (TBI)
* Diagnosis of dementia or related progressive neurocognitive disorder
* Suicidal ideation/behavior Type 4 or Type 5 intensity on C-SSRS within past 6 months of baseline
* Psychiatric inpatient treatment within past 3 months of baseline
* Treatment with electroconvulsive therapy, deep brain stimulation, vagus nerve stimulation, or transcranial magnetic stimulation within 3 months of baseline
* Implanted central nervous system device
* Treatment with evidence-based psychotherapy (EBP) for MDD or PTSD within 2 weeks prior to baseline. If receiving EBP therapy, he/she must complete treatment at least 2 weeks prior to baseline. Other forms of non-EBP psychotherapy for MDD or PTSD are allowed to continue during the study period.
* Pregnancy or lactation, or anticipated pregnancy or breastfeeding during the active treatment phase
* History of myocardial infarction, congestive heart failure, diabetic ketoacidosis, brain cancer, stroke and/or severe cardiac disease
* Clinically significant cardiac, pulmonary, renal, liver and/or other medical disease that, in the opinion of the investigator, may contraindicate the use of psilocybin, interfere with the interpretation of study results and/or constitute a health risk for the participant if they take part in the study
* Seizure disorder, except for seizures due to fever or withdrawal from a substance
* Clinically significant hypertension (\>160/95 mmHg), hypotension (\<90/60 mmHg) tachycardia (\>100 bpm at rest), QTc prolongation (\>450 msec men; \>470 msec women) or clinically significant arrhythmia on ECG
* Clinically significant abnormal laboratory results on chemistry panel, liver function tests, complete blood count, and/or thyroid stimulating hormone
* Positive urine drug screen for illicit drugs of abuse (except for THC) at screening or baseline
* Prior allergic, adverse reaction or adverse experience to a psilocybin formulation
* Litigating for disability income for a mental disorder outside the VA compensation and pension process
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
VA Office of Research and Development
FED
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lori Lynne Davis, MD AB
Role: PRINCIPAL_INVESTIGATOR
Birmingham VA Medical Center, Birmingham, AL
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Birmingham VA Medical Center, Birmingham, AL
Birmingham, Alabama, United States
Tuscaloosa VA Medical Center, Tuscaloosa, AL
Tuscaloosa, Alabama, United States
VA Portland Health Care System, Portland, OR
Portland, Oregon, United States
Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
Philadelphia, Pennsylvania, United States
VA Puget Sound Health Care System Seattle Division, Seattle, WA
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Lori L Davis, MD AB
Role: primary
Anchal Ghera, MS
Role: backup
Patricia Pilkinton, MD
Role: primary
Kaleb Murry, MS
Role: backup
Christopher Stauffer, MD
Role: primary
Michael Thase, MD
Role: primary
Rebecca Hendrickson, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MHBC-002-25S
Identifier Type: -
Identifier Source: org_study_id